Summary
28% of all primary brain tumors and central nervous system tumors and 80% of malignant tumors are gliomas, which arise from the supportive tissues in the brain. Yet, our ability to effectively treat these cancers is limited by our knowledge of the disease and our ability to test new treatments on accurate models. Advances in microfluidics and cell encapsulation within hydrogels have made significant strides in trying to meet these needs, but the potential to use these technologies for engineering physiologically relevant tissue models has yet to be fully realized. Here, we propose to investigate cancer biology using a microfluidic device with three-dimensional (3D) micro-patterned cellular constructs that may be subjected to flow through microfluidic channels. Using the developed model, we aim to understand the cellular gliomagenesis, glioma cell migration, and angiogenesis and further test drug susceptibility to demonstrate the relevance of the proposed model. To achieve these goals, I have formulated an innovative and interdisciplinary strategy based on my research experience in bottom-up tissue engineering and microfluidics, and brought together a strong team. First, I will receive an intensive training at the Max Planck Institute for Intelligent Systems on micro-robotics to strengthen the bridge between the fields of micro-robotics and bottom-up tissue engineering. Then, I will get a training at the Harvard Medical School on glioma cell culture and cell extraction from a mouse model. Finally, all these efforts will be integrated into the development of an in vitro 3D glioma-on-a-chip model mimicking the complex in vivo microenvironment of glioma. The successful completion of this timely and innovative project will result in an advanced microphysiological system that will contribute to the competitiveness of Europe in the fields of cancer management, pharmaceutics, and personalized medicine.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101003361 |
| Start date: | 01-09-2020 |
| End date: | 31-08-2022 |
| Total budget - Public funding: | 157 355,52 Euro - 157 355,00 Euro |
Cordis data
Original description
28% of all primary brain tumors and central nervous system tumors and 80% of malignant tumors are gliomas, which arise from the supportive tissues in the brain. Yet, our ability to effectively treat these cancers is limited by our knowledge of the disease and our ability to test new treatments on accurate models. Advances in microfluidics and cell encapsulation within hydrogels have made significant strides in trying to meet these needs, but the potential to use these technologies for engineering physiologically relevant tissue models has yet to be fully realized. Here, we propose to investigate cancer biology using a microfluidic device with three-dimensional (3D) micro-patterned cellular constructs that may be subjected to flow through microfluidic channels. Using the developed model, we aim to understand the cellular gliomagenesis, glioma cell migration, and angiogenesis and further test drug susceptibility to demonstrate the relevance of the proposed model. To achieve these goals, I have formulated an innovative and interdisciplinary strategy based on my research experience in bottom-up tissue engineering and microfluidics, and brought together a strong team. First, I will receive an intensive training at the Max Planck Institute for Intelligent Systems on micro-robotics to strengthen the bridge between the fields of micro-robotics and bottom-up tissue engineering. Then, I will get a training at the Harvard Medical School on glioma cell culture and cell extraction from a mouse model. Finally, all these efforts will be integrated into the development of an in vitro 3D glioma-on-a-chip model mimicking the complex in vivo microenvironment of glioma. The successful completion of this timely and innovative project will result in an advanced microphysiological system that will contribute to the competitiveness of Europe in the fields of cancer management, pharmaceutics, and personalized medicine.Status
CLOSEDCall topic
WF-02-2019Update Date
17-05-2024
Images
No images available.
Geographical location(s)
